Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.98 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Tianda Pharmaceuticals's Beneish M-Score or its related term are showing as below:
HKSE:00455'
s Beneish M-Score Range Over the Past 10 Years
Min: -2.98 Med: -2.48 Max: -1.84
Current: -2.98
During the past 13 years, the highest Beneish M-Score of Tianda Pharmaceuticals was -1.84. The lowest was -2.98. And the median was -2.48.
Tianda Pharmaceuticals Beneish M-Score Related Terms
Tianda Pharmaceuticals Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Tianda Pharmaceuticals's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianda Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Tianda Pharmaceuticals's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Tianda Pharmaceuticals for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.0028
+
0.528 * 1.1162
+
0.404 * 1.0425
+
0.892 * 0.9788
+
0.115 * 0.9852
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.9484
+
4.679 * -0.11237
-
0.327 * 1.1443
=
-2.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(38.232 / (38.232 + 386.842))
/
(38.654 / (38.654 + 384.762))
=
0.089942
/
0.091291
=
0.9852
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-69.997 - 0
-
14.036)
/
747.825
=
-0.11237
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Tianda Pharmaceuticals has a M-score of -2.98 suggests that the company is unlikely to be a manipulator.
Tianda Pharmaceuticals (HKSE:00455) has a Beneish M-Score of -2.98 as of Aug. 23, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Tianda Pharmaceuticals and its competitors. According to the industry distribution chart, Tianda Pharmaceuticals ranks #164 out of 914 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is Tianda Pharmaceuticals' Beneish M-Score too high?
Tianda Pharmaceuticals' current Beneish M-Score is -2.98. Based on the distribution chart, Tianda Pharmaceuticals ranks #164 out of 914 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianda Pharmaceuticals has a GF Score™ of 24/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tianda Pharmaceuticals' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianda Pharmaceuticals ranks #164 out of 914 companies for Beneish M-Score. This places Tianda Pharmaceuticals in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Tianda Pharmaceuticals and its competitors. Tianda Pharmaceuticals's current Beneish M-Score is -2.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tianda Pharmaceuticals (HKSE:00455) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.13, compared to a current price of HK$0.11 — trading 14.6% below its estimated fair value. The current Beneish M-Score is -2.98. Tianda Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Tianda Pharmaceuticals (HKSE:00455), the current Beneish M-Score is -2.98 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianda Pharmaceuticals (HKSE:00455) Overvalued in 2026?
Based on GuruFocus' analysis, Tianda Pharmaceuticals stock appears to be undervalued.
The current stock price of HK$0.11 is trading 14.6% below its estimated GF Value™ of HK$0.13.
GuruFocus considers Tianda Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKSE:00455:
Beneish M-Score: -2.98
GF Value™: HK$0.13 vs. price of HK$0.11 (14.6% below fair value)
No single metric tells the full story. See the HKSE:00455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianda Pharmaceuticals Ltd is engaged in research and development, manufacturing, and sales of pharmaceutical, biotechnology, and healthcare products, and investment in the development of the Chinese medicine industry. The group also engages in research and development of Chinese medicine, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services. Its operating segments include the Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives the majority of its revenue from the Pharmaceuticals and medical technologies business. Its geographical segments include Mainland China, Hong Kong, and Australia.
24GF Score
Get the complete analysis for HKSE:00455
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00455 has been successfully added to your 
